|
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Second Department of Internal Medicine (Cardiology), Sapporo Medical University School of Medicine, Sapporo, Japan
* To whom correspondence should be addressed. E-mail: dnagahar{at}sapmed.ac.jp.
| Abstract |
|---|
Despite widespread use of implantable cardioverter defibrillators (ICDs), their cost and the fact that only a certain group of patients fully benefits from the devices require appropriate risk stratification of patients. This study investigated whether altered cardiac autonomic function is associated with the occurrence of ICD discharge or lethal cardiac events. Methods: Fifty-four ICD-treated patients were prospectively followed after assessment of cardiac metaiodobenzylguanidine (MIBG) activity, quantified as the heart-to-mediastinum ratio (HMR), plasma concentration of brain natriuretic peptide (BNP), and left ventricular ejection fraction (LVEF). Patients were divided into 2 groups based on the presence (group A, n = 21) or absence (group B, n = 33) of appropriate ICD discharge during a 15-mo period. Results: Group A had a significantly lower level of MIBG activity and a higher plasma BNP level than did group B. Univariate analysis revealed BNP level, any medication, and late HMR to be significant predictors, and multivariate analysis showed late HMR to be an independent predictor. An HMR of less than 1.95 with a plasma BNP level of more than 187 pg/mL or an LVEF of less than 50% had significantly increased power to predict ICD shock: positive predictive values, 82% (HMR + BNP) and 58% (HMR + LVEF); negative predictive values, 73% (HMR + BNP) and 77% (HMR + LVEF); sensitivities, 45% (HMR + BNP) and 67% (HMR + LVEF); and specificities, 94% (HMR + BNP) and 70% (HMR + LVEF). Conclusion: When combined with plasma BNP concentration or cardiac function, cardiac MIBG activity is closely related to lethal cardiac events and can be used to identify patients who would benefit most from an ICD.
Key Words: implantable cardioverter defibrillator, metaiodobenzylguanidine imaging, brain natriuretic peptide, sudden cardiac death, lethal arrhythmias
This article has been cited by other articles:
![]() |
A. F. Jacobson, R. Senior, M. D. Cerqueira, N. D. Wong, G. S. Thomas, V. A. Lopez, D. Agostini, F. Weiland, H. Chandna, J. Narula, et al. Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure: Results of the Prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study J. Am. Coll. Cardiol., February 24, 2010; (2010) j.jacc.2010.01.014v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Gerson, M. Abdallah, J. N. Muth, and A. I. Costea Will Imaging Assist in the Selection of Patients With Heart Failure for an ICD? J. Am. Coll. Cardiol. Img., January 1, 2010; 3(1): 101 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Scott, J. Barry, P. R. Roberts, and J. M. Morgan Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis Eur J Heart Fail, October 1, 2009; 11(10): 958 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saraste, S. G. Nekolla, and M. Schwaiger Cardiovascular molecular imaging: an overview Cardiovasc Res, September 1, 2009; 83(4): 643 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Akutsu, K. Kaneko, Y. Kodama, H.-L. Li, M. Kawamura, T. Asano, K. Tanno, A. Shinozuka, T. Gokan, and Y. Kobayashi The Significance of Cardiac Sympathetic Nervous System Abnormality in the Long-Term Prognosis of Patients with a History of Ventricular Tachyarrhythmia J. Nucl. Med., January 1, 2009; 50(1): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Bax, O. Kraft, A. E. Buxton, J. G. Fjeld, P. Parizek, D. Agostini, J. Knuuti, A. Flotats, J. Arrighi, A. Muxi, et al. 123I-mIBG Scintigraphy to Predict Inducibility of Ventricular Arrhythmias on Cardiac Electrophysiology Testing: A Prospective Multicenter Pilot Study Circ Cardiovasc Imaging, September 1, 2008; 1(2): 131 - 140. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |